Elizabeth Oshnock, DO
Family Medicine · Claysville, PANPI 1750527529
Payments from drug & device makers
Across 702 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- GSK$1K
- Pfizer$1K
- AbbVie$1K
- Amgen$1K
- plus $3K from 28 others
What the payments were for
- Food & beverage$10,702100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 87 | $1,403 |
| Lilly USA, LLC | 95 | $1,324 |
| GSK | 76 | $1,316 |
| Pfizer | 79 | $1,208 |
| AbbVie | 70 | $1,037 |
| Amgen | 76 | $1,031 |
| Boehringer Ingelheim | 45 | $732 |
| AstraZeneca | 28 | $434 |
| Bayer | 19 | $291 |
| Novartis | 11 | $174 |
| Abbott | 9 | $169 |
| Esperion Therapeutics, Inc. | 17 | $158 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $155 |
| Merck | 9 | $140 |
| Biohaven Pharmaceuticals, Inc. | 9 | $137 |
| Johnson & Johnson | 9 | $131 |
| Amarin Pharma, Inc. | 6 | $110 |
| Dexcom, Inc. | 7 | $107 |
| Teva Pharmaceuticals USA, Inc. | 6 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $75 |
| Phathom Pharmaceuticals, Inc. | 5 | $74 |
| Astellas Pharma US Inc | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 5 | $66 |
| Otsuka America Pharmaceutical, Inc. | 4 | $62 |
| Exact Sciences | 3 | $58 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Edwards Lifesciences | 1 | $28 |
| Insulet Corporation | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Boston Scientific | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$10,734 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 76 | $68,393 |
| JardianceEmpagliflozin | 58 | $65,124 |
| TrulicityDulaglutide | 51 | $56,942 |
| MounjaroTirzepatide | 28 | $32,915 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $28,607 |
| OzempicSemaglutide | 15 | $25,738 |
| XareltoRivaroxaban | 27 | $19,923 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $12,238 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,402 |
| LinzessLinaclotide | 11 | $6,276 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 17 | $5,464 |
| SynthroidLevothyroxine Sodium | 55 | $4,345 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 17 | $3,750 |
| Atorvastatin Calcium | 343 | $3,441 |
| Levothyroxine Sodium | 292 | $2,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,324 | $89,85779 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $732 | $73,52670 claims |
| PfizerEliquis | $1,208 | $68,39376 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arexvy, Shingrix | $1,316 | $50,06095 claims |
| Novo NordiskOzempic | $1,403 | $25,73815 claims |
| Johnson & JohnsonXarelto | $131 | $19,92327 claims |
| AbbVieLinzess, Synthroid | $1,037 | $10,62166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Claysville
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.